Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia
Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. Howeve...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2012
|
| In: |
Leukemia and lymphoma
Year: 2011, Volume: 53, Issue: 6, Pages: 1062-1067 |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428194.2011.637210 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.3109/10428194.2011.637210 Verlag, Volltext: https://doi.org/10.3109/10428194.2011.637210 
|
| Author Notes: | Christoph Röllig, Christian Brandts, Shabnam Shaid, Marcus Hentrich, Alwin Krämer, Christian Junghanß, Eberhard Schleyer, Carsten Müller-Tidow, Wolfgang E. Berdel, Barbara Ritter, Karl-Heinz Pflüger, Michael Kramer, Martina Haibach, Gerhard Ehninger, Hubert Serve & Stefan W. Krause |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580076440 | ||
| 003 | DE-627 | ||
| 005 | 20230427065642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180815r20122011xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10428194.2011.637210 |2 doi | |
| 035 | |a (DE-627)1580076440 | ||
| 035 | |a (DE-576)510076440 | ||
| 035 | |a (DE-599)BSZ510076440 | ||
| 035 | |a (OCoLC)1341017038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Röllig, Christoph |d 1971- |e VerfasserIn |0 (DE-588)122493168 |0 (DE-627)705929116 |0 (DE-576)293296049 |4 aut | |
| 245 | 1 | 0 | |a Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia |c Christoph Röllig, Christian Brandts, Shabnam Shaid, Marcus Hentrich, Alwin Krämer, Christian Junghanß, Eberhard Schleyer, Carsten Müller-Tidow, Wolfgang E. Berdel, Barbara Ritter, Karl-Heinz Pflüger, Michael Kramer, Martina Haibach, Gerhard Ehninger, Hubert Serve & Stefan W. Krause |
| 264 | 1 | |c 2012 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 07 December 2011 | ||
| 500 | |a Gesehen am 15.08.2018 | ||
| 520 | |a Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. However, clinical data are still sparse, and there are only a few reported cases of monotherapy. The aim of the present research was to collect clinical data on efficacy and safety in a systematic way by conducting a survey on clinical experience with sorafenib. Thirty institutions were asked to document all patients treated with sorafenib diagnosed with AML. Of all 29 evaluable patients, six (21%) responded to sorafenib containing treatment by achieving a complete remission (CR, n = 2) or complete remission with incomplete platelet recovery (CRi, n = 4). In 23 patients receiving sorafenib as monotherapy, the CRi rate amounted to 13% and no CRs were documented. Of the 18 FLT-ITD positive patients with sorafenib monotherapy, two patients achieved a CRi (11%). In five FLT3-ITD negative cases, one CRi was documented (20%). Our results suggest the potential ability of the drug to induce remissions in refractory or relapsed AML even when given as monotherapy. | ||
| 534 | |c 2011 | ||
| 650 | 4 | |a Myeloid leukemias and dysplasias | |
| 650 | 4 | |a signal transduction | |
| 650 | 4 | |a signaling therapies | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 53(2012), 6, Seite 1062-1067 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia |
| 773 | 1 | 8 | |g volume:53 |g year:2012 |g number:6 |g pages:1062-1067 |g extent:6 |a Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3109/10428194.2011.637210 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.3109/10428194.2011.637210 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180815 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1580076440 |e 3022412495 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia","title_sort":"Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia"}],"name":{"displayForm":["Christoph Röllig, Christian Brandts, Shabnam Shaid, Marcus Hentrich, Alwin Krämer, Christian Junghanß, Eberhard Schleyer, Carsten Müller-Tidow, Wolfgang E. Berdel, Barbara Ritter, Karl-Heinz Pflüger, Michael Kramer, Martina Haibach, Gerhard Ehninger, Hubert Serve & Stefan W. Krause"]},"person":[{"role":"aut","given":"Christoph","display":"Röllig, Christoph","family":"Röllig"},{"family":"Krämer","given":"Alwin","role":"aut","display":"Krämer, Alwin"}],"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"recId":"1580076440","type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"title":[{"title_sort":"Leukemia and lymphoma","title":"Leukemia and lymphoma"}],"language":["eng"],"part":{"text":"53(2012), 6, Seite 1062-1067","year":"2012","volume":"53","issue":"6","extent":"6","pages":"1062-1067"},"pubHistory":["1.1989/90 -"],"recId":"324746237","origin":[{"publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedDisp":"1989-","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedKey":"1989"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2030637-4"],"issn":["1029-2403"],"eki":["324746237"]},"disp":"Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemiaLeukemia and lymphoma","note":["Gesehen am 08.09.15"]}],"note":["Published online: 07 December 2011","Gesehen am 15.08.2018"],"id":{"doi":["10.3109/10428194.2011.637210"],"eki":["1580076440"]},"physDesc":[{"extent":"6 S."}]} | ||
| SRT | |a ROELLIGCHRSURVEYANDA2012 | ||